<DOC>
	<DOC>NCT00743652</DOC>
	<brief_summary>This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.</brief_summary>
	<brief_title>Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male or female infants 6 weeks to &lt; 5years of age in good health, available for the entire study period and reachable by phone, parents able to complete all relevant study procedures. Infants who have received Prevnar are eligible to participate, but this is not required. Infants participating in the blood draws must live in a specific identified area (Yukon Kuskokwim Delta region) Contraindication to vaccination with pneumococcal vaccine or allergic reaction to any vaccines or vaccine related components, immune deficiency, bleeding disorder or major known congenital malformation.</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>13 valent Pneumococcal Conjugate Vaccine</keyword>
	<keyword>Antibody Response</keyword>
	<keyword>safety</keyword>
	<keyword>Alaskan Native Children</keyword>
</DOC>